Press Releases
Jade Biosciences to Participate in Upcoming Conferences
Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026
Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
Jade Biosciences to Participate in Upcoming Conferences
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares
Jade Biosciences Announces Pricing of Public Offering of Common Stock
Jade Biosciences Announces Proposed Underwritten Public Offering
Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy
Contact
Media Contact
Investor Contact